Skip to main content
Back to timeline
Clinical Trials & Medical DiscoveriesSource publication:

Ten63 opens BEYOND-Alpha to a select group of drugmakers, with Chugai first to nominate hard targets

Synopsis

Ten63 Therapeutics launched BEYOND-Alpha on November 18, 2026, an early adopter program in which a limited number of pharmaceutical companies work with Ten63 to apply its BEYOND computational drug design platform to challenging targets. Chugai Pharmaceutical is the first participant: it nominates targets, Ten63 generates and ranks molecular structures against each one, and Chugai holds the right to negotiate terms for further research, development and commercialization, subject to a separate definitive agreement. The program is designed to let Ten63's computational design infrastructure run across multiple drug discovery programs in parallel.

AI-generated editorial illustration: Ten63 Therapeutics Launches BEYOND-Alpha, with Chugai Pharmaceutical as First Participant

Interpretation

Ten63 Therapeutics introduced BEYOND-Alpha, an early adopter program through which a small number of pharmaceutical companies work with Ten63 to apply its BEYOND computational drug design platform to difficult targets. BEYOND had previously been presented as a platform; the new element is a collaboration channel in which outside drugmakers nominate targets and Ten63 generates and ranks molecular structures, with Chugai the first company to join. The program is explicitly limited to a small number of early participants and is designed to let Ten63's computational design infrastructure serve multiple drug discovery programs in parallel.

The division of labor is that Chugai nominates targets that challenge conventional small-molecule discovery, and Ten63 generates and ranks designed molecular structures against each target. Chugai thereby gains the right to negotiate terms for further research, development and commercialization of molecules including those structures, contingent on a separate definitive agreement. The arrangement extends an existing relationship, following the investment by Chugai Venture Fund in Ten63's strategic financing announced in February 2026.

Perspective

The scope of this item is the launch of the program and its first participant, aimed at researchers and engineers interested in how computational drug design enters pharmaceutical discovery pipelines; the announcement names no collaboration targets, molecule counts or experimental results.

Chugai holds only a right to negotiate terms for further research, development and commercialization of the molecules, contingent on a separate definitive agreement, so the collaboration has not entered a defined development stage; the announcement also does not state a cap on participants or a program duration.